Portola Pharmaceuticals, Inc.
) has been putting in substantial efforts to develop its
pipeline. We believe that the pipeline at Portola must deliver to
facilitate the company's long-term growth. Currently, the company
does not have any marketed products.
Portola is dedicated to develop and commercialize products
catering to unmet needs of patients suffering from thrombosis,
other hematologic disorders and inflammation.
The company has started a phase I/II proof-of-concept study on
its oral dual spleen tyrosine kinase (Syk) and janus kinase (JAK)
inhibitor candidate, PRT2070.
PRT2070 is being evaluated for patients suffering from
genetically-defined hematologic cancers and patients who have not
responded to prior therapy due to relapse or acquired
The open-label, multicenter, proof-of-concept study will
examine oral PRT2070's safety, pharmacokinetics and
pharmacodynamics profile. In the multi dose,dose esc phase I
portion of the study, the candidate will be administered to
sequential dose groups at increasing dose levels until the
maximum tolerated dose is ascertained. Safety and efficacy
measures for cancer types discovered in the phase I part will be
evaluated in the phase II part (cohort expansion).
We note that Portola has a co-development and
co-commercialization agreement with Aciex Therapeutics, Inc for
PRT2070. Per the agreement, each party will be responsible for
its own internal research and development costs. Until the end of
phase II study, Aciex will bear 60% and Portola will bear 40% of
the costs related to third-party development.
We remind investors that, Portola's another pipeline candidate
PRT4445, performed encouragingly in a phase II proof-of-concept
study earlier in the year. The candidate aims to reverse the
Factor Xa inhibitor's anticoagulant activity in patients
suffering from uncontrolled bleeding or undergoing emergency
Portola carries a Zacks Rank #4 (Sell). Companies that
currently look well-positioned include
Endo Health Solutions Inc.
) with a Zacks Rank #1 (Strong Buy) and
Alexion Pharmaceuticals, Inc.
) with a Zacks Rank #2 (Buy).
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis
ENDO PHARMACEUT (ENDP): Free Stock Analysis
PORTOLA PHARMA (PTLA): Free Stock Analysis
To read this article on Zacks.com click here.